FAQ on CNS Pharmaceuticals CEO's Feature in Virtual Investor CEO Connect

What is the Virtual Investor CEO Connect?

The Virtual Investor CEO Connect is a platform where CEOs of companies, like CNS Pharmaceuticals, present their company’s overview and engage in a live Q&A session with investors.

Who is participating from CNS Pharmaceuticals in the Virtual Investor CEO Connect?

John Climaco, the CEO of CNS Pharmaceuticals, will be participating in the Virtual Investor CEO Connect.

When is the Virtual Investor CEO Connect webcast featuring CNS Pharmaceuticals CEO?

The webcast is scheduled to begin at 12 p.m. ET on Aug. 26, 2024.

How can I view the live webcast of the Virtual Investor CEO Connect?

The live webcast can be viewed by visiting https://ibn.fm/E4Fki.

What will be discussed during the webcast?

During the webcast, John Climaco will present an overview of CNS Pharmaceuticals and participate in a live Q&A session.

What is CNS Pharmaceuticals’ lead drug candidate?

CNS Pharmaceuticals’ lead drug candidate is Berubicin, a novel anthracycline designed to treat serious brain and CNS oncology indications, including glioblastoma multiforme (GBM).

Where can I find more information about CNS Pharmaceuticals?

More information about CNS Pharmaceuticals can be found on their website at www.CNSPharma.com or in their newsroom at https://ibn.fm/CNSP.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the company’s website following the presentation.

What is the significance of CNS Pharmaceuticals’ participation in the Virtual Investor CEO Connect?

This participation highlights CNS Pharmaceuticals’ commitment to transparency and engagement with investors, showcasing their developments in treating brain and central nervous system cancers.